Skip to main content

Advertisement

SpringerLink
Log in

Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

We investigated the efficacy of cilostazol treatment for 2 years on the attenuation of carotid intima-media thickness (IMT) progression in type 2 diabetic patients without cardiovascular disease history, as compared with other antiplatelet agents. We recruited a total of 230 type 2 diabetic patients who had undergone IMT measurement twice within 1.5–2.5 years (mean 2.06 ± 0.32 years) interval. Among these participants, we classified them into three groups according to antiplatelet agent administration at baseline: Group I (n = 66), antiplatelet naïve; Group II (n = 75), other antiplatelet agent administration; and Group III (n = 50), cilostazol administration. We then analyzed the changes in clinical characteristics from baseline to 2 years. The changes in annual mean IMT at 2 years were 0.019 ± 0.045 mm/year, −0.001 ± 0.058 mm/year, and −0.019 ± 0.043 mm/year for Group I, II, and III, respectively (P < 0.001). Mean change in total cholesterol, low-density lipoprotein-cholesterol, and triglyceride compared with baseline decreased the most in Group III even after adjustment for statin use. We also observed that the odds ratio of carotid IMT progression at 2 years was the lowest in patients who were treated with cilostazol even after adjustment for change of metabolic parameters. When we categorized patients according to baseline carotid IMT tertile, the efficacy of cilostazol against carotid IMT progression was significant only when baseline IMT was over 0.662 mm (mean 0.801). Two-year treatment with cilostazol strongly inhibited carotid IMT progression compared to other antiplatelet agents in type 2 diabetic patients. This beneficial effect of cilostazol was significant when baseline IMT was thicker than 0.662 mm (mean 0.801 mm).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339(4), 229–234 (1998)

    Article  CAS  PubMed  Google Scholar 

  2. P. Koskinen, M. Manttari, V. Manninen, J.K. Huttunen, O.P. Heinonen, M.H. Frick, Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15(7), 820–825 (1992)

    Article  CAS  PubMed  Google Scholar 

  3. R. Kawamori, Y. Yamasaki, H. Matsushima, H. Nishizawa, K. Nao, H. Hougaku, H. Maeda, N. Handa, M. Matsumoto, T. Kamada, Prevalence of carotid atherosclerosis in diabetic patients. Ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care 15(10), 1290–1294 (1992)

    Article  CAS  PubMed  Google Scholar 

  4. T.J. Smilde, S. van Wissen, H. Wollersheim, M.D. Trip, J.J. Kastelein, A.F. Stalenhoef, Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357(9256), 577–581 (2001)

    Article  CAS  PubMed  Google Scholar 

  5. M.W. Lorenz, H.S. Markus, M.L. Bots, M. Rosvall, M. Sitzer, Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115(4), 459–467 (2007)

    Article  PubMed  Google Scholar 

  6. M.R. Langenfeld, T. Forst, C. Hohberg, P. Kann, G. Lubben, T. Konrad, S.D. Fullert, C. Sachara, A. Pfutzner, Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111(19), 2525–2531 (2005)

    Article  CAS  PubMed  Google Scholar 

  7. E. Lonn, S. Yusuf, V. Dzavik, C. Doris, Q. Yi, S. Smith, A. Moore-Cox, J. Bosch, W. Riley, K. Teo, S. Investigators, Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103(7), 919–925 (2001)

    Article  CAS  PubMed  Google Scholar 

  8. B. Hedblad, J. Wikstrand, L. Janzon, H. Wedel, G. Berglund, Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 103(13), 1721–1726 (2001)

    Article  CAS  PubMed  Google Scholar 

  9. J. Kambayashi, Y. Liu, B. Sun, Y. Shakur, M. Yoshitake, F. Czerwiec, Cilostazol as a unique antithrombotic agent. Curr. Pharm. Des. 9(28), 2289–2302 (2003)

    Article  CAS  PubMed  Google Scholar 

  10. Y. Han, Y. Li, S. Wang, Q. Jing, Z. Wang, D. Wang, Q. Shu, X. Tang, Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am. Heart J. 157(4), 733–739 (2009)

    Article  CAS  PubMed  Google Scholar 

  11. H. Ota, M. Eto, M.R. Kano, S. Ogawa, K. Iijima, M. Akishita, Y. Ouchi, Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28(9), 1634–1639 (2008)

    Article  CAS  PubMed  Google Scholar 

  12. S.Y. Park, H.K. Shin, J.H. Lee, C.D. Kim, W.S. Lee, B.Y. Rhim, K.W. Hong, Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription. J. Pharmacol. Exp. Ther. 329(2), 571–579 (2009)

    Article  CAS  PubMed  Google Scholar 

  13. D.F. Geng, J. Deng, D.M. Jin, W. Wu, J.F. Wang, Effect of cilostazol on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. Atherosclerosis 220(1), 177–183 (2012)

    Article  CAS  PubMed  Google Scholar 

  14. C.M. Ahn, S.J. Hong, J.H. Park, J.S. Kim, D.S. Lim, Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessel 26(5), 502–510 (2011)

    Article  Google Scholar 

  15. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1), S62–S69 (2010)

    Article  PubMed Central  Google Scholar 

  16. J.H. Moon, M.K. Chae, K.J. Kim, H.M. Kim, B.S. Cha, H.C. Lee, Y.J. Kim, B.W. Lee, Decreased endothelial progenitor cells and increased serum glycated albumin are independently correlated with plaque-forming carotid artery atherosclerosis in type 2 diabetes patients without documented ischemic disease. Circ. J. 76(9), 2273–2279 (2012)

    Article  CAS  PubMed  Google Scholar 

  17. S.K. Kim, S.W. Park, S.H. Kim, B.S. Cha, H.C. Lee, Y.W. Cho, Visceral fat amount is associated with carotid atherosclerosis even in type 2 diabetic men with a normal waist circumference. Int. J. Obes (Lond) 33(1), 131–135 (2009)

    Article  CAS  Google Scholar 

  18. P.J. Touboul, M.G. Hennerici, S. Meairs, H. Adams, P. Amarenco, N. Bornstein, L. Csiba, M. Desvarieux, S. Ebrahim, M. Fatar, R. Hernandez, M. Jaff, S. Kownator, P. Prati, T. Rundek, M. Sitzer, U. Schminke, J.C. Tardif, A. Taylor, E. Vicaut, K.S. Woo, F. Zannad, M. Zureik, Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the advisory board of the 3rd and 4th watching the risk symposium, 13th and 15th european stroke conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc. Dis 23(1), 75–80 (2007)

    Article  PubMed  Google Scholar 

  19. G.K. Hansson, Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352(16), 1685–1695 (2005)

    Article  CAS  PubMed  Google Scholar 

  20. American Diabetes Association, Standards of medical care in diabetes—2011. Diabetes Care 34(Suppl 1), S11–S61 (2011)

    Article  PubMed Central  Google Scholar 

  21. N. Katakami, Y.S. Kim, R. Kawamori, Y. Yamasaki, The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 121(23), 2584–2591 (2010)

    Article  CAS  PubMed  Google Scholar 

  22. S.U. Kwon, Y.J. Cho, J.S. Koo, H.J. Bae, Y.S. Lee, K.S. Hong, J.H. Lee, J.S. Kim, Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36(4), 782–786 (2005)

    Article  CAS  PubMed  Google Scholar 

  23. A.K. Kamal, I. Naqvi, M.R. Husain, B.A. Khealani, Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst. Rev. (1), CD008076 (2011)

  24. M. Rizzo, E. Corrado, A.M. Patti, G.B. Rini, D.P. Mikhailidis, Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin. Pharmacother. 12(4), 647–655 (2011)

    Article  CAS  PubMed  Google Scholar 

  25. H. Ueno, H. Koyama, Y. Mima, S. Fukumoto, S. Tanaka, T. Shoji, M. Emoto, T. Shoji, Y. Nishizawa, M. Inaba, Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. J. Atheroscler. Thromb. 18(10), 883–890 (2011)

    Article  CAS  PubMed  Google Scholar 

  26. V.J. Dzau, R.C. Braun-Dullaeus, D.G. Sedding, Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 8(11), 1249–1256 (2002)

    Article  CAS  PubMed  Google Scholar 

  27. M.A. Feijge, K. Ansink, K. Vanschoonbeek, J.W. Heemskerk, Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Biochem. Pharmacol. 67(8), 1559–1567 (2004)

    Article  CAS  PubMed  Google Scholar 

  28. N.K. Agrawal, R. Maiti, D. Dash, B.L. Pandey, Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol. Res. 56(2), 118–123 (2007)

    Article  CAS  PubMed  Google Scholar 

  29. T. Wada, Y. Onogi, Y. Kimura, T. Nakano, H. Fusanobori, Y. Ishii, M. Sasahara, H. Tsuneki, T. Sasaoka, Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions. Eur. J. Pharmacol. 707(1–3), 120–129 (2013)

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Korea Science and Engineering Foundation (KOSEF) and grant funded by the Korean government (MOST) (No. R13-2002-054-04002-0). Dong-Su Jang, B.A. (Research Assistant, Department of Anatomy, Yonsei University College of Medicine, Seoul, Korea) supplied figures upon request. The authors thank Hye Kyung Kim of the Yonsei University Medical Library for helping prepare this manuscript.

Conflict of interest

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Korea

    Ji Hye Huh, Hannah Seok, Byung-Wan Lee, Eun Seok Kang, Hyun Chul Lee & Bong Soo Cha

Authors
  1. Ji Hye Huh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hannah Seok
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Byung-Wan Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eun Seok Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hyun Chul Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bong Soo Cha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bong Soo Cha.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 176 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huh, J.H., Seok, H., Lee, BW. et al. Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event. Endocrine 47, 138–145 (2014). https://doi.org/10.1007/s12020-013-0120-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-013-0120-y

Keywords

Search

Navigation